Clinical trials: Antitumor Drug
Lymphoma, Advanced Solid Tumors
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intratumorally in participants with advanced solid tumors or lymphomas.
- Trial name
- NCT04144140
- Testing
- E7766
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 24 people
- Sponsor
- Eisai Inc.
Endometrial Neoplasms, Uterine Neoplasms
Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
The purpose of this is to test the safety and effectiveness of an investigational chemotherapy agent in patients with persistent or recurrent endometrial cancer.
- Conditions
- Endometrial Neoplasms, Uterine Neoplasms, Genital Neoplasms, Female Urogenital Neoplasms
- Trial name
- NCT00050440
- Testing
- Trabectedin, Dexamethasone
- Where
- 14 sites in United States, Canada and 2 more
- Volunteers
- 50 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Melanoma
A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
A Phase 2 study investigating the efficacy and safety of ONCOS-102 alone or in combination with balstilimab (a programmed death receptor-1 [PD-1] inhibitor).
- Trial name
- NCT05561491
- Testing
- ONCOS-102, Balstilimab
- Sponsor
- Targovax Oy
Solid Tumors, Cancer
Phase I Study of Oral DFP-11207 in Solid Tumors
This is a first-in-human, open label, single arm, sequential dose escalation and expansion study of oral DFP-11207 in patients with advanced solid tumors.
- Trial name
- NCT02171221
- Testing
- Oral DFP-11207
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Delta-Fly Pharma, Inc.
Breast Cancer, Solid Tumors
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2).
- Trial name
- NCT05262400
- Testing
- PF-07220060 + PF-07104091 combination dose escalation, PF-07104091 + PF-07220060 + fulvestrant dose expansion, PF-07104091 + PF-07220060 + letrozole dose expansion
- Where
- 44 sites in United States, Argentina and 7 more
- Volunteers
- 235 people
- Sponsor
- Pfizer
Antineoplastic Adverse Reaction, Thrombocytopenia
Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
Chemotherapy-related myelosuppression usually occurs in AML patients, which induces severe thrombocytopenia and haemorrhage, a leading cause of death.
- Conditions
- Antineoplastic Adverse Reaction, Thrombocytopenia, Acute Myelocytic Leukemia
- Trial name
- NCT02244658
- Testing
- rhTPO
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shandong University
Protein Kinase Inhibitors, Antineoplastic Protocols
A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.
The purpose of this study is to assess JNJ-26483327 (a drug in development for cancer) for the safety of the drug in patients with advanced solid tumors that have not responded or are no longer responding to available therapies.
- Conditions
- Protein Kinase Inhibitors, Antineoplastic Protocols, Clinical Trial, Phase 1, Maximum Tolerated Dose
- Trial name
- NCT00676299
- Testing
- JNJ-26483327
- Volunteers
- 19 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Extravasation
A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines
The purpose of this study is To prevent progression of a lesion caused by anthracycline extravasation into necrosis, which would require surgical intervention To prevent development of deep tissue necrosis and destruction leading…
- Trial name
- NCT00548704
- Testing
- Dexrazoxane
- Where
- 34 sites in Denmark, Germany and 3 more
- Volunteers
- 57 people
- Sponsor
- Valerio Therapeutics
Breast Neoplasms, Survival Analysis
Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients
The genetic polymorphisms of the cytochrome P450 may influence on the metabolism of tamoxifen. The investigators want to evaluate the frequency or incidence of the genetic polymorphisms of cytochrome P450 subfamilies(CYP2D6…
- Conditions
- Breast Neoplasms, Survival Analysis, Antineoplastic Agents, Therapeutic Uses
- Trial name
- NCT01169792
- Testing
- tamoxifen
- Where
- 2 sites in South Korea
- Sponsor
- Yonsei University
Neoplasms Malignant
A Phase 1 Dose Escalation and Expansion Study of AK117
This is a multicenter, open label, single arm, Phase 1，dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacodynamics, PK, immunogenicity, and preliminary antitumor activity of AK117…
- Trial name
- NCT04728334
- Testing
- AK117
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Akeso
HER2-positive Advanced Solid Tumor
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
- Trial name
- NCT05150691
- Testing
- DB-1303/BNT323, Pertuzumab Injection, Ritonavir
- Where
- 102 sites in United States, Australia and 4 more
- Volunteers
- 796 people
- Sponsor
- DualityBio Inc.
Breast Neoplasm
Adjuvant Endocrine Therapy in Early Stage Breast Cancer: Adherence and Clinical Outcome
Breast cancer is the most common cancer among women in Norway. In 2016, 3402 new cases were diagnosed (3371 in women). Breast cancer is still the second most common cause of death from cancer among women with 585 breast cancer…
- Trial name
- NCT03761420
- Where
- Norway
- Volunteers
- 1,411 people
- Sponsor
- St. Olavs Hospital
Advanced Solid Tumor
Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
This research study is a multicentre phase Ⅰb/Ⅱ Study to evaluate the efficacy and safety of SHR-A1921 in combination with other anti-cancer agents in patients with advanced solid tumors
- Trial name
- NCT05765032
- Testing
- SHR-A1921；
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Oral Mucositis, Oral Mucositis (Ulcerative) Due to Radiation
Copaíba-based Mouthwash in Oral Mucotitis Prevention and Treatment in Oral Cancer Patients During Radioteraphy
Oral mucositis is the most significant acute toxicity of oral cavity radiotherapy. The available scientific evidence supports its preventive and therapeutic approach with low-level laser; however, this is unsuitable for tumor…
- Conditions
- Oral Mucositis, Oral Mucositis (Ulcerative) Due to Radiation, Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy, Oral Mucositis Due to Radiation
- Trial name
- NCT06708702
- Testing
- Copaíba mouthwash
- Where
- 2 sites in Brazil
- Sponsor
- Instituto Nacional de Cancer, Brazil
Heart Failure, Cardiotoxicity
The STOP-MED CTRCD Trial
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients.
- Conditions
- Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity
- Trial name
- STOP-MED CTRCD (NCT06183437)
- Testing
- Stopping Heart Failure Medication(s)
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 335 people
- Sponsor
- Dinesh Thavendiranathan
Breast Cancer, Colorectal Cancer
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody.
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT04244552
- Testing
- ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD)
- Where
- 19 sites in United States
- Volunteers
- 87 people
- Sponsor
- Atreca, Inc.
Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
This phase I trial tests the safety, side effects and best dose of glofitamab given with alternating cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)/ rituximab, dexamethasone, cytarabine…
- Conditions
- Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma
- Trial name
- NCT07444710
- Testing
- Biospecimen Collection, Cisplatin, Computed Tomography
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Thromboembolism, Cancer
Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic Therapy
This is a multicentric, phase IV study. In this study patients that are receiving an antineoplastic treatment and that have been diagnosed with venous thromboembolism will receive edoxaban as per clinical practice.
- Trial name
- EDOI (NCT04072068)
- Testing
- Edoxaban
- Where
- 18 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Metastatic Solid Tumor Cancer
First-in-human Phase I to Evaluate PEP-010 as Single Agent and in Combination With Paclitaxel or With Gemcitabine (CleverPeptide)
This is an open-label, non-controlled, multicenter, dose escalation, first-in-human phase I clinical trial with an expansion phase designed to assess the safety, tolerability, PK and PD parameters, and preliminary antitumor…
- Trial name
- Clever Peptide (NCT04733027)
- Testing
- Dose escalation, first-in-human phase I clinical trial with an Expansion phase
- Where
- 4 sites in France
- Volunteers
- 77 people
- Sponsor
- Institut Curie
Prostate Cancer
Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00002597
- Testing
- flutamide, Zoladex, Lupron
- Where
- 239 sites in United States, Canada
- Volunteers
- 2,028 people
- Sponsor
- Radiation Therapy Oncology Group